NCT02050737

Brief Summary

This is an exploratory, translational, non-interventional and multi-centre clinical study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
109

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2013

Longer than P75 for all trials

Geographic Reach
1 country

14 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 23, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 31, 2014

Completed
7.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 13, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 13, 2021

Completed
Last Updated

July 8, 2025

Status Verified

July 1, 2025

Enrollment Period

7.8 years

First QC Date

January 23, 2014

Last Update Submit

July 4, 2025

Conditions

Keywords

Curative resectionAdjuvant chemotherapy

Outcome Measures

Primary Outcomes (1)

  • Disease free survival or progression free survival

    Identify plasma biomarkers with improved sensitivity to predict early recurrence of CRAC and presence of residual occult metastases following completion of adjuvant chemotherapy

    Duration of treatment and follow up, expected to be 4 years

Secondary Outcomes (2)

  • Accuracy, sensitivity, specificity and concordance index

    Duration of treatment and follow up period, expected to be 4 years

  • To investigate the correlation between biomarkers identified in plasma samples with the expression of the same biomarkers at tissue level.

    For the duration of treatment and follow up, expected to be 4 years

Study Arms (2)

A - due for adjuvant chemotherapy

Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy

B - for observation only

Stage II colorectal cancer with resectable disease for observation only

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

100 CRAC patients with stage II/III resectable disease due for adjuvant chemotherapy. 30 CRAC patients with stage II resectable disease for observation only.

You may qualify if:

  • Patient must be able to give written informed consent
  • Histologically or cytologically confirmed CRAC
  • Cohort A: colorectal cancer patients with stage II/III resectable disease due for adjuvant chemotherapy OR Cohort B: colorectal cancer patients with stage II resectable disease for observation only
  • Age ≥ 18 years
  • Treatment with curative intent
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0 - 2

You may not qualify if:

  • Presence of a medical or psychiatric condition, which, in the opinion of the investigator, would potentially pose a risk to the patient when participating in this trial
  • Evidence of a metastatic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Beacon Hospital

Bracken Rd, Sandyford Industrial Estate, Dublin 18, Ireland

Location

Our Lady of Lourdes Hospital Drogheda

Drogheda, Louth, Ireland

Location

Bon Secours Hosptial

Cork, Ireland

Location

Cork Universtiy Hospital

Cork, Ireland

Location

Letterkenny General Hospital

Donegal, Ireland

Location

Adelaide & Meath Hospital incorporating National Children's Hoptial (AMNCH)

Dublin, 4, Ireland

Location

Mater Misericordiae University Hospital

Dublin, 7, Ireland

Location

St James Hospital

Dublin, 8, Ireland

Location

Beaumont Hospital

Dublin, 9, Ireland

Location

St Vincent's Hospital

Dublin, Ireland

Location

Galway University Hospital

Galway, Ireland

Location

Midwestern Regional Hosptial, Limerick

Limerick, Ireland

Location

Sligo General Hospital

Sligo, Ireland

Location

Waterford Regional Hospital

Waterford, Ireland

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 23, 2014

First Posted

January 31, 2014

Study Start

October 1, 2013

Primary Completion

July 13, 2021

Study Completion

July 13, 2021

Last Updated

July 8, 2025

Record last verified: 2025-07

Locations